Skip to main content
Fig. 3 | Biomarker Research

Fig. 3

From: Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody

Fig. 3

Difference in serum sCD26 titer variation between SD and PD cohorts by bar graph analysis. The difference of serum sCD26 titer variation from baseline (day 1pre, 100%) on day 1pre, day 15pre and day 29pre of YS110 administration between SD and PD cohorts was analyzed. Analyzed data were stratified into a total 23 cases, b 17 cases with Q2W administration, c 14 male cases with Q2W administration, d 8 cases with Q1W administration, e 17 MM cases, f 11 MM cases with Q2W administration, f 9 MM, male cases with Q2W administration, h 6 RCC cases with Q2W administration. Data are shown as mean ± S.D. in each group

Back to article page